Addendum to Commission A13-03
(sitagliptin/metformin)¹

Addendum

Commission: A13-29
Version: 1.0
Status: 29 August 2013

¹Translation of the document “Addendum zum Auftrag A13-03 (Sitagliptin/Metformin)” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.
Publishing details

Publisher
Institute for Quality and Efficiency in Health Care

Topic:
Addendum to Commission A13-03 (sitagliptin/metformin)

Commissioning agency:
Federal Joint Committee

Commission awarded on:
6 August 2013

Internal Commission No.:
A13-29

Address of publisher:
Institute for Quality and Efficiency in Health Care
Im Mediapark 8 (KölnTurm)
50670 Cologne
Germany

Tel.: +49 (0)221 – 35685-0
Fax: +49 (0)221 – 35685-1
E-Mail: berichte@iqwig.de
Internet: www.iqwig.de
IQWiG employees involved in the addendum:\(^2\):
- Helmut Hörn
- Lars Beckmann
- Thomas Kaiser

Keywords: sitagliptin, metformin, diabetes mellitus – type 2, benefit assessment

\(^2\) Due to legal data protection regulations, employees have the right not to be named.
Table of contents

List of tables ............................................................................................................................. iv
List of figures ............................................................................................................................ v
List of abbreviations ................................................................................................................ vi
1 Background ........................................................................................................................ 1
2 Assessment .......................................................................................................................... 2
   2.1 Research question A1: sitagliptin/metformin versus sulfonylurea
       (glibenclamide, glimepiride) plus metformin ........................................................... 3
   2.2 Research question A2: sitagliptin/metformin versus glipizide plus metformin .... 7
3 References ......................................................................................................................... 13
Appendix A – Forest plots of the subgroup analyses for the characteristic
"metformin dose", sitagliptin/metformin versus glimepiride plus metformin................. 14
Appendix B – Forest plots of the subgroup analyses for the characteristic
"metformin dose", sitagliptin/metformin versus glipizide plus metformin................. 17
List of tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Distribution of the patients according to the metformin dose in the studies P803 and P024</td>
<td>2</td>
</tr>
<tr>
<td>Table 2</td>
<td>Results (dichotomous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin</td>
<td>3</td>
</tr>
<tr>
<td>Table 3</td>
<td>Results (continuous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin</td>
<td>6</td>
</tr>
<tr>
<td>Table 4</td>
<td>Results – RCT, direct comparison: combination sitagliptin/metformin vs. glipizide plus metformin</td>
<td>8</td>
</tr>
</tbody>
</table>
Addendum to Commission A13-03 Version 1.0
(sitagliptin/metformin) 29 August 2013

List of figures

Figure 1: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) all-cause mortality – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ................................................................................................................................. 14

Figure 2: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ........................................................ 14

Figure 3: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ...................................................................................................... 15

Figure 4: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) overall rate of serious adverse events – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ........................................................................................... 15

Figure 5: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) treatment discontinuations due to adverse events – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ........................................................ 16

Figure 6: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) health-related quality of life – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin ...................................................................................................... 16

Figure 7: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) all-cause mortality – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ................................................................................................................................. 17

Figure 8: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 52 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 17

Figure 9: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 104 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 18

Figure 10: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias week 0 to 52 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 18

Figure 11: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias week 0 to 104 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 19

Figure 12: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) overall rate of serious adverse events – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 19

Figure 13: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) treatment discontinuations due to adverse events – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin ........................................................ 20
### List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>appropriate comparator therapy</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>G-BA</td>
<td><em>Gemeinsamer Bundesausschuss</em> (Federal Joint Committee)</td>
</tr>
<tr>
<td>HbA1c</td>
<td>glycosylated haemoglobin A1c</td>
</tr>
<tr>
<td>IQWiG</td>
<td><em>Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen</em> (Institute for Quality and Efficiency in Health Care)</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
</tbody>
</table>
1 Background

On 6 August 2013 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-03 ([1], fixed combination of sitagliptin and metformin, hereinafter referred to as "sitagliptin/metformin").

The studies P803 and P024 presented by the pharmaceutical company (hereinafter abbreviated to "the company") could not be used in the original benefit assessment for the assessment of the added benefit of sitagliptin/metformin because it was unclear how many patients received a metformin dose of ≥ 1700 mg/day, which concurs with the approval of the fixed combination sitagliptin/metformin, and because the company did not prove that the results of the studies were independent from the metformin dose administered. However, it was noted in the assessment report: "In case of a proof that the results of both studies do not depend on the metformin dose, the results cited in the dossier assessment A13-02 could also be used for the fixed combination sitagliptin/metformin."

In the commenting procedure on the assessment of sitagliptin/metformin, the company submitted further data to the G-BA that went beyond the information in the dossier. These refer to separate analyses of the data according to metformin exposition:

- Patients with a metformin dose of < 1700 mg/day
- Patients with an approval-compliant metformin dose of ≥ 1700 mg/day

These data were presented for the 2 studies P803 (comparison of sitagliptin plus metformin versus glimepiride plus metformin) and P024 (comparison of sitagliptin plus metformin versus glipizide plus metformin).

The commission of the G-BA for the assessment of the added benefit of the fixed combination of sitagliptin and metformin reads as follows: "Assessment of the documents submitted in the commenting procedure, particularly with regards to the study population with a minimum dosage of 1700 mg metformin."

In Chapter 2, the documents subsequently submitted are presented and assessed according to the commission, considering the same outcomes as for the assessment of the free combination of sitagliptin and metformin [2].

The responsibility for the present assessment and the results of the assessment lies exclusively with IQWiG. The assessment is forwarded to the G-BA. The G-BA decides on the added benefit.
2 Assessment

The distribution of the patients according to the metformin dose in the 2 studies P803 and P024 is presented in Table 1.

Table 1: Distribution of the patients according to the metformin dose in the studies P803 and P024

<table>
<thead>
<tr>
<th>Metformin dose</th>
<th>Study P803</th>
<th>Study P024</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sitagliptin/metformin</td>
<td>Glimepiride plus metformin</td>
</tr>
<tr>
<td>N = 516</td>
<td>N = 518</td>
<td>N = 588</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>&lt; 1700 mg/day</td>
<td>185 (35.9)</td>
<td>178 (34.4)</td>
</tr>
<tr>
<td>≥ 1700 mg/day</td>
<td>324 (62.8)</td>
<td>333 (64.3)</td>
</tr>
<tr>
<td>n.d.</td>
<td>7 (1.4)</td>
<td>7 (1.4)</td>
</tr>
</tbody>
</table>

a: All randomized patients according to the allocated treatment arm.  
N: number of analysed patients; n: number of patients in the dose category; n.d.: no data

The majority of patients in both studies received an approval-compliant metformin dose of ≥ 1700 mg/day (64% of the patients in the study P803 and 73% of the patients in the study P024). Due to the low number of patients without data on the metformin dose, the results of the subgroup analyses for the characteristic "metformin dose" are presented below only for patients for whom data on the metformin dose are available. The company did not present any patient characteristics for the patients with an approval-compliant metformin dose of ≥ 1700 mg/day.

The results from the subgroup analyses for the characteristic "metformin dose" on the comparison of sitagliptin/metformin versus glimepiride plus metformin (as operationalization of the appropriate comparator therapy [ACT] specified by the G-BA, research question A1 of the assessment A13-03) are presented in Section 2.1. The results from the subgroup analyses for the characteristic "metformin dose" on the comparison additionally commissioned by the G-BA (sitagliptin/metformin versus glipizide plus metformin, research question A2 of the assessment A13-03) are presented in Section 2.2. The results for the total population from the assessment report and for the free combination of sitagliptin plus metformin [2] and – if provided by the company – the results from the subgroup analyses for the characteristic "metformin dose" are presented. The data subsequently submitted by the company were, where necessary, supplemented by the Institute’s calculations. The tables contain results on the overall rate of adverse events (AEs) and on the change in body weight as additional information.

The odds ratio (OR) offers a good approximation of the relative risk (RR) in low numbers of events. Hence in event rates of ≤ 1% (in at least one cell), the Peto OR instead of the RR was calculated as effect measure and used for the assessment.
2.1 Research question A1: sitagliptin/metformin versus sulfonylurea (glibenclamide, glimepiride) plus metformin

Table 2 and Table 3 present the results for the comparison of sitagliptin/metformin versus glimepiride plus metformin. The forest plots of the subgroup analyses for the characteristic "metformin dose" can be found in Appendix A.

Table 2: Results (dichotomous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin

<table>
<thead>
<tr>
<th>Study Population</th>
<th>Sitagliptin/metformin</th>
<th>Glimepiride plus metformin</th>
<th>Sitagliptin/metformin vs. glimepiride plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (^a) Patients with events n (%)</td>
<td>N (^a) Patients with events n (%)</td>
<td>RR/Peto-OR(^b) [95% CI]; p-value(^c)</td>
</tr>
<tr>
<td>P803</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td>516 0 (0)</td>
<td>518 1 (0.2)</td>
<td>0.14 [0.00; 6.85]; p &gt; 0.999</td>
</tr>
<tr>
<td>&lt; 1700 mg/day</td>
<td>185 0 (0)</td>
<td>178 1 (0.7)</td>
<td>0.13 [0.00; 6.56]</td>
</tr>
<tr>
<td>≥ 1700 mg/day</td>
<td>324 0 (0)</td>
<td>333 0 (0)</td>
<td>n.c.</td>
</tr>
<tr>
<td>Interaction(^d)</td>
<td>n.c.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac morbidity(^e)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td>516 2 (0.4)</td>
<td>518 2 (0.4)</td>
<td>1.00 [0.14; 7.15]; p &gt; 0.999(^f)</td>
</tr>
<tr>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>Cerebral morbidity(^g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td>516 1 (0.2)</td>
<td>518 2 (0.4)</td>
<td>0.51 [0.05; 4.96]; p = 0.584(^f)</td>
</tr>
<tr>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>AEs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemias</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomatic hypoglycaemias (blood glucose ≤ 50 mg/dl)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total population</td>
<td>516 3 (0.6)</td>
<td>518 33 (6.4)</td>
<td>0.18 [0.09; 0.35]; p &lt; 0.001(^f)</td>
</tr>
<tr>
<td>&lt; 1700 mg/day</td>
<td>185 0 (0)</td>
<td>178 10 (5.6)</td>
<td>0.12 [0.04; 0.43]</td>
</tr>
<tr>
<td>≥ 1700 mg/day</td>
<td>324 3 (0.9)</td>
<td>333 22 (6.6)</td>
<td>0.21 [0.10; 0.47]; p = 0.476</td>
</tr>
</tbody>
</table>

(continued)
Table 2: Results (dichotomous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin (continuation)

<table>
<thead>
<tr>
<th>Study Outcome category</th>
<th>Outcome Population</th>
<th>Sitagliptin/metformin</th>
<th>Glimepiride plus metformin</th>
<th>Sitagliptin/metformin vs. glimepiride plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Patients with events n (%)</td>
<td>N</td>
<td>Patients with events n (%)</td>
</tr>
<tr>
<td>Severe hypoglycaemias</td>
<td>Total population</td>
<td>516 1 (0.2)</td>
<td>518 3 (0.6)</td>
<td>0.37 [0.05; 2.62]; p = 0.624&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>185 0 (0)</td>
<td>178 0 (0)</td>
<td>n.c.</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>324 1 (0.3)</td>
<td>333 3 (0.9)</td>
<td>0.38 [0.05; 2.68]</td>
</tr>
<tr>
<td></td>
<td>Interaction&lt;sup&gt;d&lt;/sup&gt;</td>
<td>n.c.</td>
<td>n.c.</td>
<td>n.c.</td>
</tr>
<tr>
<td>Change in HbA1c</td>
<td>Neither data on the course of HbA1c nor on the difference between the start and the end of the study were available for patients with a metformin dose of ≥ 1700 mg/day.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Total population</td>
<td>516 1 (0.2)</td>
<td>518 0 (0)</td>
<td>7.42 [0.15; 373.83]; p = 0.499&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>Renal impairment&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Total population</td>
<td>516 0 (0)</td>
<td>518 0 (0)</td>
<td>n.c.</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>Overall rate AEs&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Total population</td>
<td>516 244 (47.3)</td>
<td>518 291 (56.2)</td>
<td>n.c.</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>185 87 (47.0)</td>
<td>178 95 (53.4)</td>
<td>n.c.</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>324 152 (46.9)</td>
<td>333 193 (58.0)</td>
<td>n.c.</td>
</tr>
<tr>
<td></td>
<td>Interaction&lt;sup&gt;d&lt;/sup&gt;</td>
<td>n.c.</td>
<td>n.c.</td>
<td>n.c.</td>
</tr>
<tr>
<td>Overall rate SAEs&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Total population</td>
<td>516 16 (3.1)</td>
<td>518 11 (2.1)</td>
<td>1.46 [0.68; 3.12]; p = 0.338&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>185 5 (2.7)</td>
<td>178 3 (1.7)</td>
<td>1.60 [0.39; 6.61]</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>324 11 (3.4)</td>
<td>333 8 (2.4)</td>
<td>1.41 [0.58; 3.47]</td>
</tr>
<tr>
<td></td>
<td>Interaction&lt;sup&gt;d&lt;/sup&gt;</td>
<td>p = 0.883</td>
<td>p = 0.883</td>
<td>p = 0.883</td>
</tr>
<tr>
<td>Treatment discontinuations due to AEs&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Total population</td>
<td>516 10 (1.9)</td>
<td>518 2 (0.4)</td>
<td>3.86 [1.24; 12.05]; 0.020</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>185 3 (1.6)</td>
<td>178 0 (0)</td>
<td>7.19 [0.74; 69.61]</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>324 6 (1.9)</td>
<td>333 2 (0.6)</td>
<td>2.83 [0.70; 11.38]</td>
</tr>
<tr>
<td></td>
<td>Interaction&lt;sup&gt;d&lt;/sup&gt;</td>
<td>p = 0.492</td>
<td>p = 0.492</td>
<td>p = 0.492</td>
</tr>
</tbody>
</table>

(continued)
Table 2: Results (dichotomous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin (continuation)

| a | All randomized patients according to the allocated treatment arm, or number of patients with a metformin dose of ≥ 1700 mg/day. |
| b | Peto OR provided in event numbers ≤ 1% in at least one cell. |
| c | Fisher's exact test. |
| d | Institute's calculation, meta-analysis with random effects according to DerSimonian and Laird. Missing observations were not considered. |
| e | Serious cardiac events. MedDRA SOC “cardiac disorders”, without deaths. |
| f | Institute's calculation. |
| g | Serious cerebral events. MedDRA SOC “nervous system disorders”, without deaths. |
| h | Serious renal events. MedDRA SOC “renal and urinary disorders”, without deaths. |
| i | Hypoglycaemias were also recorded here, with hypoglycaemias occurring neither in the SAEs nor in the treatment discontinuations due to AEs. |

AE: adverse event; CI: confidence interval; HbA1c: glycosylated haemoglobin A1c; MedDRA: Medical Dictionary for Regulatory Activities; N: Number of analysed patients; n: number of patients with event; n.c.: not calculated; n.d.: no data; OR: odds ratio; RCT: randomized controlled trial; RR: relative risk; SAE: serious adverse event; SOC: System Organ Class according to MedDRA; vs.: versus
Table 3: Results (continuous outcomes) – RCT, direct comparison: sitagliptin/metformin vs. glimepiride plus metformin

<table>
<thead>
<tr>
<th>Study</th>
<th>Outcome category</th>
<th>Sitagliptin/metformin</th>
<th>Glimepiride plus metformin</th>
<th>Sitagliptin/metformin vs. glimepiride plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population</td>
<td>Outcome</td>
<td>Population</td>
<td></td>
</tr>
<tr>
<td>P803</td>
<td>Health-related quality of life</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EQ-5D (VAS)</td>
<td>N(^a)</td>
<td>Change at end of study mean (SD)</td>
<td>N(^a)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>173</td>
<td>2.1 (8.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>309</td>
<td>2.0 (7.9)</td>
</tr>
<tr>
<td></td>
<td>Interaction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supplementary outcome &quot;body weight&quot;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Body weight</td>
<td>N(^a)</td>
<td>Values at start of study mean (SD)</td>
<td>N(^a)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Change in body weight at week 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total population</td>
<td>465</td>
<td>80.6 (15.2)</td>
<td>-0.8 (3.0)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>165</td>
<td>n.d.</td>
<td>-0.8 (2.4)</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>294</td>
<td>n.d.</td>
<td>-0.8 (3.2)</td>
</tr>
</tbody>
</table>

\(^a\): Unless stated otherwise, LOCF analysis of the ITT population. Includes all patients according to their randomization who received at least one dose of the study medication and for whom a baseline and at least one further measurement were available or, out of this, number of patients with a metformin dose of ≥ 1700 mg/day.

\(^b\): Adjusted for country and baseline value.

\(^c\): Cochran-Mantel-Haenszel test.

\(^d\): Negative values mean disadvantage of sitagliptin/metformin.

CI: confidence interval; EQ-5D: European Quality of Life-5 Dimensions; ITT: intention to treat; LOCF: last observation carried forward; N: number of analysed patients; n.c.: not calculated; n.d.: no data; RCT: randomized controlled trial; SD: standard deviation; VAS: visual analogue scale

The subgroup analyses for the characteristic "metformin dose" showed neither indications nor proof of an interaction for the outcomes "all-cause mortality", "overall rate of SAEs" and "treatment discontinuations due to AEs" (p ≥ 0.2). Moreover, the effect estimates of the subgroups showed in the same direction and were of similar magnitude in the patient group with a metformin dose of ≥ 1700 mg/day and in the total population. An effect modification...
could not be finally assessed for the outcomes "all-cause mortality" and "overall rate of SAEs" due to the small number of events.

The subgroup analyses on health-related quality of life for the characteristic "metformin dose" showed proof of an interaction (p = 0.016). This did not result in different conclusions for patients with a metformin dose of ≥ 1700 mg/day versus those with a metformin dose of < 1700 mg/day. The result was not statistically significant in the patient group with a metformin dose of ≥ 1700 mg/day. In the patient group with a metformin dose of < 1700 mg/day, the result was statistically significant to the disadvantage of sitagliptin, but the upper limit of the 95% confidence interval of the standardized mean difference was -0.06 and thus above the irrelevance threshold of -0.2 [3].

The company provided no subgroup analyses for the characteristic "metformin dose" for the outcomes "cardiac morbidity", "cerebral morbidity", "renal impairment" and "pancreatitis". Since no more than 2 patients in each treatment arm had an event in the total population, an effect modification could also not have been assessed for these outcomes.

Neither indications nor proof of an interaction were shown for the outcomes "symptomatic hypoglycaemias (blood glucose ≤ 50 mg/dl)" and "severe hypoglycaemias" (p ≥ 0.2). The company did not provide data on the courses of glycosylated haemoglobin A1c value (HbA1c values) or the HbA1c values at the start and end of the study in the subpopulations. Since there were no relevant differences between subpopulations and total population in the remaining outcomes, however, this did not raise fundamental doubts about the interpretation of the results on hypoglycaemias in the subpopulations.

**Summary**

It can be assumed for most outcomes that there was no effect modification by the metformin dose or that this was not relevant for the assessment. Overall, it seems possible to use the analyses of the total population of the study P803 presented in the dossier assessment A13-02 also for the assessment of the fixed combination sitagliptin/metformin versus glimepiride plus metformin.

**2.2 Research question A2: sitagliptin/metformin versus glipizide plus metformin**

The results for the comparison of sitagliptin/metformin versus glipizide plus metformin are presented in Table 4. The forest plots of the subgroup analyses for the characteristic "metformin dose" can be found in Appendix B.
Table 4: Results – RCT, direct comparison: combination sitagliptin/metformin vs. glipizide plus metformin

<table>
<thead>
<tr>
<th>Study</th>
<th>Outcome category</th>
<th>Outcome Population</th>
<th>Sitagliptin/metformin</th>
<th>Glipizide plus metformin</th>
<th>Sitagliptin/metformin vs. glipizide plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Patients with events n (%)</td>
<td>N&lt;sup&gt;a&lt;/sup&gt; Patients with events n (%)</td>
<td>RR/Peto-OR&lt;sup&gt;b&lt;/sup&gt; [95% CI]; p-value&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>P024&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Mortality</td>
<td>All-cause mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total population</td>
<td>588</td>
<td>1 (0.2)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158</td>
<td>1 (0.6)</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429</td>
<td>0 (0)</td>
<td>427</td>
</tr>
<tr>
<td></td>
<td>Morbidity</td>
<td>Cardiac morbidity&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total population</td>
<td>588</td>
<td>15 (2.6)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>Cerebral morbidity&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total population</td>
<td>588</td>
<td>2 (0.3)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>Health-related quality of life</td>
<td>Not recorded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AEs</td>
<td>Symptomatic hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total population</td>
<td>588</td>
<td>4 (0.7)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158</td>
<td>0 (0)</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429</td>
<td>4 (0.9)</td>
<td>427</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interaction&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptomatic hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 104</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total population</td>
<td>588</td>
<td>5 (0.9)</td>
<td>584</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158</td>
<td>0 (0)</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429</td>
<td>5 (1.2)</td>
<td>427</td>
</tr>
</tbody>
</table>

(continued)
Table 4: Results – RCT, direct comparison: combination sitagliptin/metformin vs. glipizide plus metformin (continuation)

<table>
<thead>
<tr>
<th>Study Outcome category</th>
<th>Sitagliptin/metformin</th>
<th>Glipizide plus metformin</th>
<th>Sitagliptin/metformin vs. glipizide plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Outcome category</td>
<td>N^a Patients with events n (%)</td>
<td>N^a Patients with events n (%)</td>
</tr>
<tr>
<td>Severe hypoglycaemias week 0 to 52</td>
<td>Total population</td>
<td>588 1 (0.2)</td>
<td>584 7 (1.2)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158 0 (0)</td>
<td>157 3 (1.9)</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429 1 (0.2)</td>
<td>427 4 (0.9)</td>
</tr>
<tr>
<td></td>
<td>Interaction^c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe hypoglycaemias week 0 to 104</td>
<td>Total population</td>
<td>588 1 (0.2)</td>
<td>584 9 (1.5)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158 0 (0)</td>
<td>157 3 (1.9)</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429 1 (0.2)</td>
<td>427 6 (1.4)</td>
</tr>
<tr>
<td></td>
<td>Interaction^c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in HbA1c</td>
<td>Neither data on the course of HbA1c nor on the difference between the start and the end of the study were available for patients with a metformin dose of ≥ 1700 mg/day.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Total population</td>
<td>588 2^k (0.3^g)</td>
<td>584 0 (0)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>Renal impairment^i</td>
<td>Total population</td>
<td>588 4 (0.7)</td>
<td>584 4 (0.7)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>Overall rate AEs^l</td>
<td>Total population</td>
<td>588 452 (76.9)</td>
<td>584 480 (82.2)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158 126 (79.7)^j</td>
<td>157 136 (86.6)^j</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429 334 (77.9)^j</td>
<td>427 348 (81.5)^j</td>
</tr>
<tr>
<td>Overall rate SAEs^l,m</td>
<td>Total population</td>
<td>588 64 (10.9)</td>
<td>584 73 (12.5)</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158 16 (10.1)</td>
<td>157 16 (10.2)</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429 48 (11.2)</td>
<td>427 57 (13.3)</td>
</tr>
<tr>
<td></td>
<td>Interaction^c</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
Table 4: Results – RCT, direct comparison: combination sitagliptin/metformin vs. glipizide plus metformin (continuation)

<table>
<thead>
<tr>
<th>Study Outcome category</th>
<th>Outcome Population</th>
<th>Sitagliptin/metformin</th>
<th>Glipizide plus metformin</th>
<th>Sitagliptin/metformin vs. glipizide plus metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N² Patients with events n (%)</td>
<td>N² Patients with events n (%)</td>
<td>RR/Peto-ORᵇ [95% CI]; p-valueᶜ</td>
<td></td>
</tr>
<tr>
<td>Treatment discontinuations due to AEsᵇδ</td>
<td>Total population</td>
<td>588 23 (3.9)</td>
<td>584 29 (5.0)</td>
<td>0.79 [0.46; 1.35]; p = 0.398ᵍ</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>158 6 (3.8)</td>
<td>157 10 (6.4)</td>
<td>0.60 [0.22; 1.60]</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>429 25 (5.8)</td>
<td>427 25 (5.6)</td>
<td>1.00 [0.58; 1.70]</td>
</tr>
<tr>
<td>Interactionᵉ</td>
<td>p = 0.372</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N²</th>
<th>Values at start of study mean (SD)</th>
<th>Change at end of study mean (SD)</th>
<th>N²</th>
<th>Values at start of study mean (SD)</th>
<th>Change at end of study mean (SD)</th>
<th>ΔLSM* [95% CI]; p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight week 52</td>
<td>Total population</td>
<td>547 89.4 (16.9)</td>
<td>-1.3 (0.3)</td>
<td>534 89.5 (17.1)</td>
<td>1.2 (0.3)</td>
<td>-2.5 [-3.1; -2.0]; n.d.</td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>—</td>
</tr>
<tr>
<td>Body weight week 104</td>
<td>Total population</td>
<td>Not presented in assessment report A13-02ʰ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt; 1700 mg/day</td>
<td>Not presented in addendumⁱ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 1700 mg/day</td>
<td>Not presented in addendumⁱ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a: All patients as treated, or, out of this, number of patients with a metformin dose of ≥ 1700 mg/day.
b: Peto OR provided in event numbers ≤ 1% in at least one cell.
c: Fisher's exact test.
d: Unless stated otherwise, the results after 104 weeks are presented.
e: Institute's calculation, meta-analysis with random effects according to DerSimonian and Laird. Missing observations were not considered.
f: Serious cardiac events. MedDRA SOC “cardiac disorders”, without deaths.
g: Institute's calculation.
h: Serious cerebral events. MedDRA SOC “nervous system disorders”, without deaths.
i: Serious renal events. MedDRA SOC “renal and urinary disorders”, without deaths.
j: The sum of patients with one AE or with treatment discontinuation due to AE is greater in the subgroups (metformin dose of < 1700 mg/day vs. ≥ 1700 mg/day) than the respective number of patients with one AE or with treatment discontinuation due to AE in the total population.
k: 2 events are mentioned in the dossier. One patient with pancreatitis and one patient with chronic pancreatitis are cited in the clinical study report. It cannot be reconstructed from this information whether these were 2 different patients.

(continued)
Table 4: Results – RCT, direct comparison: combination sitagliptin/metformin vs. glipizide plus metformin (continuation)

| l: | Hypoglycaemic events were also recorded here. There were no hypoglycaemias as SAEs in the study P024. 4 patients in the glipizide arm discontinued treatment due to hypoglycaemias. Without these 4 patients, the values of the 2 groups approach each other further. |
| m: | Non-fatal SAEs. |
| n: | Unless stated otherwise, LOCF analysis of the ITT population. Includes all patients according to their randomization who received at least one dose of the study medication and for whom a baseline and at least one further measurement were available or, out of this, number of patients with a metformin dose of ≥1700 mg/day. |
| o: | Adjusted for prior treatment and baseline values. |
| p: | Change at end of study and difference of the change at end of study were estimated using an ANCOVA. Missing values were imputed using LOCF. |
| q: | Only analysis without replacement of missing values available. The data are not presented because the proportion of the patients who were not considered in the analysis was >30% and the difference of the proportions of patients who were not considered was more than 15 percentage points between the treatment arms. |
| ALSM: | difference calculated with the least squares method; AE: adverse event; ANCOVA: analysis of covariance; CI: confidence interval; HbA1c: glycated haemoglobin A1c; ITT: intention to treat; LOCF: last observation carried forward; MedDRA: Medical Dictionary for Regulatory Activities; N: number of analysed patients; n: number of patients with event; n.d.: no data; OR: odds ratio; RCT: randomized controlled trial; RR: relative risk; SAE: serious adverse event; SD: standard deviation; SOC: System Organ Class according to MedDRA; vs.: versus |

The subgroup analyses for the characteristic "metformin dose" showed neither indications nor proof of an interaction for the outcomes "all-cause mortality", "overall rate of SAEs" and "treatment discontinuations due to AEs" (p ≥ 0.2). Moreover, the effect estimates of the subgroups showed in the same direction and were of similar magnitude in the patient group with a metformin dose of ≥1700 mg/day and in the total population.

The company provided no subgroup analyses for the characteristic "metformin dose" for the outcomes "cardiac morbidity", "cerebral morbidity", "renal impairment" and "pancreatitis". Since only few events occurred in the total population, an effect modification could not have been assessed for the outcomes "renal impairment" and "pancreatitis". It remained unclear for cardiac and cerebral morbidity whether an effect modification was present. However, these outcomes did not lead to a derivation of an added benefit of sitagliptin for the total population either, because the result in the total population was not statistically significant.

Neither indications nor proof of an interaction were shown for the outcomes "symptomatic hypoglycaemias (blood glucose ≤50 mg/dl)" and "severe hypoglycaemias" (p ≥ 0.2). The company did not provide data on the courses of HbA1c values or the HbA1c values at the start or end of the study in the subpopulations. Since there were no relevant differences between subpopulations and total population in the remaining outcomes, however, this did not raise fundamental doubts about the interpretation of the results on hypoglycaemias in the subpopulations.
Summary

It can be assumed for most outcomes that there was no effect modification from the metformin dose or that this was not relevant for the assessment. Overall, it seems possible to use the analyses of the total population of the study P024 presented in the dossier assessment A13-02 also for the assessment of the fixed combination sitagliptin/metformin versus glipizide plus metformin.
3 References


Appendix A – Forest plots of the subgroup analyses for the characteristic "metformin dose", sitagliptin/metformin versus glimepiride plus metformin

Figure 1: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) all-cause mortality – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin

Figure 2: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin
Figure 3: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin

<table>
<thead>
<tr>
<th>Study pool</th>
<th>sitagliptin/metformin</th>
<th>glimepiride+metformin</th>
<th>Peto OR (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1700mg metformin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P803</td>
<td>0/185</td>
<td>0/178</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥1700mg metformin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P803</td>
<td>1/324</td>
<td>3/333</td>
<td>0.38 [0.05, 2.68]</td>
<td>100.0</td>
</tr>
<tr>
<td>All</td>
<td>1/509</td>
<td>3/511</td>
<td>0.38 [0.05, 2.68]</td>
<td></td>
</tr>
</tbody>
</table>

Sitagliptin/metformin vs. glimepiride+metformin
Severe hypoglycaemic events
Random effects model - DerSimonian and Laird
Heterogeneity among study pools: Q=0.02, df=1, p=0.883, I²=0%
Overall effect: Z Score=0.99, p=0.323, Tau=0

Figure 4: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) overall rate of serious adverse events – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin

<table>
<thead>
<tr>
<th>Study pool</th>
<th>sitagliptin/metformin</th>
<th>glimepiride+metformin</th>
<th>RR (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1700mg metformin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P803</td>
<td>5/185</td>
<td>3/178</td>
<td>1.60 [0.39, 6.61]</td>
<td>100.0</td>
</tr>
<tr>
<td>≥1700mg metformin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P803</td>
<td>11/324</td>
<td>8/333</td>
<td>1.41 [0.58, 3.47]</td>
<td>100.0</td>
</tr>
<tr>
<td>All</td>
<td>16/509</td>
<td>11/511</td>
<td>1.47 [0.69, 3.13]</td>
<td></td>
</tr>
</tbody>
</table>

Sitagliptin/metformin vs. glimepiride+metformin
Serious adverse events
Random effects model - DerSimonian and Laird
Heterogeneity among study pools: Q=0.02, df=1, p=0.883, I²=0%
Overall effect: Z Score=0.99, p=0.323, Tau=0

Heterogeneity among study pools: Q=0.02, df=1, p=0.883, I²=0%
Figure 5: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) treatment discontinuations due to adverse events – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin

Figure 6: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) health-related quality of life – RCT, direct comparison: sitagliptin/metformin versus glimepiride plus metformin
Appendix B – Forest plots of the subgroup analyses for the characteristic "metformin dose", sitagliptin/metformin versus glipizide plus metformin

Figure 7: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) all-cause mortality – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin

Figure 8: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 52 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin
Figure 9: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) confirmed hypoglycaemias (blood glucose ≤ 50 mg/dl) week 0 to 104 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin

Figure 10: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias week 0 to 52 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin
Figure 11: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) severe hypoglycaemias week 0 to 104 – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin

Figure 12: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) overall rate of serious adverse events – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin
Figure 13: Subgroup analysis (metformin dose < 1700 mg/day versus ≥ 1700 mg/day) treatment discontinuations due to adverse events – RCT, direct comparison: sitagliptin/metformin versus glipizide plus metformin